Introduction
Intracavernous injection therapy for the treatment of erectile disfunction (ED) was introduced during the 1980s and has since became a common form of therapy. 1 Prostaglandin E 1 (PGE 1 ) solutions for intracavernous injection therapy have been reported to be superior or at least equal in ef®ciency, when compared to other erectogenic agents. 2 Diluted aqueous PGE 1 solutions have been reported to have limited stability. The stability of several PGE 1 solutions have been reported. 3 ± 5 The present study describes the preparation and packing of a PGE 1 solution in saline (20 mga0.5 ml, pH 4.5) with stability for up to 6 months, when kept at 5 C.
Materials and methods

Injection preparation
Two ampoules (Prostin VR, Pharmacia & Upjohn, Milan, Italy), containing 0.5 mg of PGE 1 each, were used to prepare a 25 ml solution in sterile saline (NaCl 0.9%). This solution (20 mg PGE 1 a0.5 ml), was used to ®ll 50 sterile 0.5 ml insulin syringes (Beckton Dickenson, Dublin, Ireland) to the 0.5 ml mark without any air bubbles. All syringes were recapped and 25 syringes were stored at 5 C and the other 25 syringes stored at room temperature for stability analyses at predetermined stages. Drug dilution was performed under aseptic conditions in a laminar¯ow cabinet in a class 1000 clean room. All analyses were done in duplicate at 4 week intervals for 24 weeks on all syringes. Syringes stored at 5 C were then analyzed at 10-week intervals up to 54 weeks. Those stored at room temperature were only analyzed until the remaining PGE 1 concentration in solution fell below 70%.
Chromatography
All analyses were done according to the chromatography method described by Fraccaro et al. 3 A Shimadzu 10 A HPLC system with a sample autoinjector and a diode array detector (SPD M 10A) set to wavelength 193 nm, with pump speed at 1.0 mlamin, was used. Psherisorb (Phase Sept), 3 micron particle size, 15 cm, C8 column at ambient temperature, with the mobile phase of water (HPLCgrade, Burdick & Jackson, MI, USA): phosphoric acid (Merck, Lichrosolve, Darmstadt, Germany): acetonitrile (Merck, Lichrosolve) (64 : 0.02 : 36) and the injection volume of 50 ml, was used.
Sample preparation
A stock solution containing 0.5 mg PGE 1 (Sigma, Atlasville, South Africa) in ethanol (Merck, Lichrosolve) was prepared and three standard solutions in sterile saline (NaCl 0.9%) containing 15, 20 and 25 mg PGE 1 a0.5 ml were made from this preparation. Aliquots (0.15 ml) of the three standard solutions as well as the packed syringes were taken to dryness with a Roto Vac rotary vacuum device. The residue was reconstituted with 0.15 ml mobile phase and injected into the HPLC.
The peak areas were used to calculate a linear 3-point calibration curve. The PGE 1 concentration in the syringes was then determined from this curve. The points re¯ected 75%, 100%, and 125% of the initial PGE 1 concentration. The percentage coef®cient of variation (% CV) at the target value (20 mga0.5 ml) was 1.93 (n 5). One hundred per cent of the analyte was recovered and no interfering peaks co-eluted with the PGE 1 (5.6 minutes) peak.
Results
The PGE 1 concentration in the aseptically prepared syringes stored at 5 C, remained above 90% of the initial PGE 1 concentration for up to 24 weeks. From week 24 to week 34, a decline in the PGE 1 concentration was noticed. This decline leveled out from week 34 to week 54, with a mean value of 73% of the initial PGE 1 concentration.
The PGE 1 concentration in the syringes stored at room temperature (21 C), declined to 90% of the initial PGE 1 concentration within 6 weeks. This was followed by a further decline in PGE 1 concentration to 63% after 20 weeks. This trend of initial PGE 1 stability, followed by lowering and leveling out of the PGE 1 concentration, had the same pattern found in diluted solutions of PGE 1 in water as reported by Fraccaro et al. 3 The initial stability followed by rapid decomposition was also reported for the E-class prostaglandins in triacetin. 5 It was suggested to be due to catalyses of the decomposed product.
Conclusion
Increased stability of diluted PGE 1 in saline (pH 4.5) and buffered saline (pH 4.7) solutions compared to phosphate buffered water (pH 7.4) stored at 37 C have been reported. 4 A PGE 1 solution (20 mgaml) prepared in a saline and ethanol mixture stored at 4 C had a stability of 15.24 weeks. 6 In the current study, the more concentrated PGE 1 (20 mga0.5 ml) in saline solution, stored at 5 C, had a higher stability compared to the stability found in the other studies of PGE 1 solutions (20 mgaml) in water or saline. The solution containing 20 mg PGE 1 per 0.5 ml normal saline stored at 5 C, maintained a concentration of 90% of the initial PGE 1 solution for up to 24 weeks.
The increased stability in this concentrated PGE 1 in saline solution may have clinical application. This solution when aseptically prepared, may be packed in ready to use, unit dose syringes, for use in an auto-injector specially designed for these syringes (Autoject 2 TM , Owen Mumford, UK). 7 When applied to intracavernous injection therapy, the more concentrated PGE 1 solution with less volume may simplify the injection procedure and reduce the risk of scarring and infection.
